Evoke Pharma Management
Management criteria checks 2/4
Evoke Pharma's CEO is Matt D'Onofrio, appointed in Mar 2024, has a tenure of less than a year. total yearly compensation is $857.37K, comprised of 52.5% salary and 47.5% bonuses, including company stock and options. directly owns 0.23% of the company’s shares, worth €8.43K. The average tenure of the management team and the board of directors is 3.8 years and 16.9 years respectively.
Key information
Matt D'Onofrio
Chief executive officer
US$857.4k
Total compensation
| CEO salary percentage | 52.5% |
| CEO tenure | less than a year |
| CEO ownership | 0.2% |
| Management average tenure | 3.8yrs |
| Board average tenure | 16.9yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$857k | US$450k | -US$8m |
| Sep 30 2023 | n/a | n/a | -US$8m |
| Jun 30 2023 | n/a | n/a | -US$8m |
| Mar 31 2023 | n/a | n/a | -US$8m |
| Dec 31 2022 | US$602k | US$417k | -US$8m |
| Sep 30 2022 | n/a | n/a | -US$8m |
| Jun 30 2022 | n/a | n/a | -US$8m |
| Mar 31 2022 | n/a | n/a | -US$8m |
| Dec 31 2021 | US$1m | US$407k | -US$9m |
| Sep 30 2021 | n/a | n/a | -US$9m |
| Jun 30 2021 | n/a | n/a | -US$9m |
| Mar 31 2021 | n/a | n/a | -US$14m |
| Dec 31 2020 | US$828k | US$387k | -US$13m |
| Sep 30 2020 | n/a | n/a | -US$12m |
| Jun 30 2020 | n/a | n/a | -US$12m |
| Mar 31 2020 | n/a | n/a | -US$7m |
| Dec 31 2019 | US$852k | US$372k | -US$7m |
| Sep 30 2019 | n/a | n/a | -US$7m |
| Jun 30 2019 | n/a | n/a | -US$7m |
| Mar 31 2019 | n/a | n/a | -US$8m |
| Dec 31 2018 | US$831k | US$357k | -US$8m |
| Sep 30 2018 | n/a | n/a | -US$6m |
| Jun 30 2018 | n/a | n/a | -US$10m |
| Mar 31 2018 | n/a | n/a | -US$9m |
| Dec 31 2017 | US$780k | US$345k | -US$12m |
Compensation vs Market: Matt's total compensation ($USD857.37K) is above average for companies of similar size in the German market ($USD402.64K).
Compensation vs Earnings: Matt's compensation has increased whilst the company is unprofitable.
CEO
Matt D'Onofrio (53 yo)
less than a year
Tenure
US$857,371
Compensation
Mr. Matthew J. D'Onofrio, also known as Matt, MBA, had been the Chief Business Officer and Executive Vice President at Evoke Pharma, Inc. since 2010 until 2023. He served as Treasurer and Secretary since M...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | less than a year | US$857.37k | 0.23% $ 8.4k | |
| Chief Medical Officer | 10.4yrs | US$728.49k | 0.051% $ 1.8k | |
| Chief Commercial Officer - Gimoti (TM) | 3.8yrs | no data | no data |
3.8yrs
Average Tenure
Experienced Management: EV00's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | less than a year | US$857.37k | 0.23% $ 8.4k | |
| Independent Director | 16.9yrs | US$77.54k | 0% $ 0 | |
| Independent Director | 16.9yrs | US$79.43k | 0.0039% $ 141.7 | |
| Independent Chairman of the Board | 16.9yrs | US$102.95k | 0.33% $ 11.9k | |
| Independent Director | 16.9yrs | US$79.18k | 0.019% $ 682.0 | |
| Independent Director | 3yrs | US$89.25k | 0% $ 0 |
16.9yrs
Average Tenure
63.5yo
Average Age
Experienced Board: EV00's board of directors are seasoned and experienced ( 16.9 years average tenure).